This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Boehringer Ingelheim GmbH
Drug Names(s): Spiriva HandiHaler, tiotropium bromide, Ba 679 BR, Spiriva Respimat
Spiriva is a once-daily, dry powder formulation of an anticholinergic with specificity for muscarinic receptors. Inhaled muscarinic antagonists block the effect of acetylcholine at its muscarinic receptor, leading to airway smooth muscle relaxation and bronchodilation. The HandiHaler uses a dry powder formulation, and the Respimat an aqueous solution.
This drug entry also includes information on Ba 679 BR Respimat, which is tiotropium bromide inhaled using the Respimat device.
Revenue splits for this drug are BioMedTracker estimates.
Spiriva was discovered and developed by Boehringer Ingelheim. In April 2001, Boehringer Ingelheim and Pfizer announced that they had entered into a long-term worldwide agreement to jointly market Spiriva.
Partners: Pfizer Inc.
Pink Sheet Spiriva FDA Reviewers
Pink Sheet Spiriva Clinical Development
Additional information available to subscribers only: